Introduction

Human papillomavirus (HPV) is a causative agent in cervical, anal, oropharyngeal, penile, and vaginal/vulvar cancers [1–5]. HPV types 16 and 18 are responsible for >90% of HPV-associated cancers; [6] however, a number of additional types have been identified as carcinogenic [7]. Analysis of 2008–2012 data from the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program, determined that approximately 30,700 incident cancers attributable to HPV occurred in the United States each year [8]. The rates per 100,000 persons (age-adjusted to the 2000 U.S. standard population) of histologically confirmed HPV-associated cancers by site are 7.4 for cervical cancer (female only), 4.5 for oropharyngeal squamous cell carcinoma of Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Licensed, safe, and effective vaccines to protect against new HPV infections, including types 16 and 18, are currently available; these include bivalent, quadrivalent, and nonavalent vaccines, each initially licensed for administration according to a 3-dose schedule. In 2014, the World Health Organization reviewed noninferiority data and evidence from studies with alternative dosing regimens [9–12] and recommended a 2-dose (0, 6 months “prime-boost”) schedule of bivalent or quadrivalent vaccine for females 9–14 years of age, with vaccination of males receiving lower priority [13]. Several countries have adopted 2-dose regimens and gender-restricted HPV vaccination programs, despite the clear public health importance of universal (both males and females) vaccination [14, 15]. In the United States, a 2-dose schedule is currently under consideration by the Advisory Committee on Immunization Practices (ACIP) but is not yet recommended. Presently, the ACIP recommends routine vaccination of both males and females at 11 or 12 years of age. Specific recommendations include administering HPV vaccine up to age 21 for males and up to age 26 for females, males who have sex with males, and immunocompromised individuals [16–19]. HPV vaccines offer primary prevention of cervical cancer and afford protection against other HPV-associated cancers. In 2014, only 39.7% of girls and 21.6% of boys 13–17 years of age completed the HPV vaccine 3-dose series in the United States [20]. Rates of vaccination against HPV are even lower in the United States among 19–26 year olds, particularly among the uninsured [20]. Populations vulnerable to health disparities, such as racial/ethnic minority groups, those with low income, limited English proficiency, or who are under- or uninsured, also have lower HPV vaccine completion rates [21]. Lower rates of vaccination among these groups may compound already-existing socioeconomic and racial/ethnic disparities for several HPV-associated cancers – including cervical, oropharyngeal, and vaginal cancers [22].

Reasons for poor HPV vaccine coverage in the United States have been described and include parent-related factors, with ‘lack of knowledge’ and lack of physician recommendation being primary reasons cited among parents for not vaccinating their children [20, 23]. Additional barriers described by parents include inconsistent use of preventive services among adolescents and teens, the cost of vaccination, low perceived risk of HPV infection, and concerns around the potential impact on sexual behavior [23]. Parental attitudes and financial concerns have been cited as barriers to offering the vaccine by healthcare providers [23]. System-level barriers, such as lack of school-based vaccination program or mandates, and insurance coverage have also been frequently identified [23]. These and other factors were thoroughly reviewed by Jacobson and colleagues [24].

The President’s Cancer Panel report identified the need to increase HPV vaccination as a public health priority and outlined three goals toward achieving increased HPV vaccination coverage in the United States: reducing missed clinical opportunities to recommend and administer HPV vaccines; increasing acceptance of HPV vaccination; and maximizing access to HPV vaccination services [25]. The research described herein was undertaken with these three goals in mind and a focus on traditionally underserved populations and populations suffering greater cancer burden. Specifically, the purpose of this study was to assess awareness and knowledge of HPV disease, HPV-related cancers, and HPV vaccines among adults attending a community-based volunteer clinic for the working uninsured. Little is known about whether individuals who receive their routine health care in volunteer-based health care settings are reached by HPV vaccine messaging and cancer-related education. Our research addresses this gap in the evidence base and characterizes HPV-related knowledge and attitudes among an uninsured, working, and ethnically and racially diverse population.

Materials and Methods

Design and setting

This cross-sectional, community-based study was approved by the Institutional Review Board of Mayo Clinic and conducted at the Volunteers in Medicine Clinic (VIM) in Jacksonville, Florida (FL). The VIM clinic provides free primary care for working individuals without insurance who meet certain income requirements and live and/or work in Duval County, FL. Health care providers at VIM include volunteers who practice at other local health care organizations, in addition to full time staff. Approximately 1800 adult patients are seen annually; a majority (about 70%) of patients are female and over half are members of racial or ethnic minority groups. Currently, HPV vaccination is not offered at VIM due to cost considerations and a low volume of pediatric/adolescent patients.

Instrument development and measures

The content of the survey was informed by general knowledge of the clinic population and review of existing measures of HPV vaccine attitudes and knowledge. Demographic characteristics included sex, age, race, ethnicity, marital status, employment status, number of children, and formal
Adult knowledge of Human Papillomavirus

C. Radecki Breitkopf et al.

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

edual knowledge of Human Papillomavirus

Patients who were not in acute distress, understood English or Spanish, and provided oral consent to participate in a research study were offered a survey. Patients who returned a survey received a thank you gift and the HPV Fact Sheet developed by the Centers for Disease Control and Prevention.

Data from the 2014 Health Information National Trends Survey (HINTS 4, Cycle 4) regarding HPV knowledge and vaccine awareness were used as a national benchmark against which to compare data from the VIM sample. HINTS is a nationally representative survey of the U.S. adult population focused on cancer-related knowledge, attitudes, and behavior [27]. Data for HINTS 4, Cycle 4, were collected between July and November 2014 through self-administered mailed questionnaires. Further details regarding HINTS methodology and questionnaires can be found on the HINTS website [28].

Analysis

Demographic characteristics were assessed overall and for those who had heard of HPV and the HPV vaccine. All three knowledge scores were created by equal weight summation. Furthermore, if survey participants responded as being unaware of HPV or the HPV vaccine, their respective knowledge scores were imputed to zero. High knowledge for HPV disease, HPV vaccines, and HPV-related cancer was defined as having a knowledge score in the upper quartile of positive values (≥75th percentile of knowledge scores ≥1). Odds ratios (OR) and 95% confidence intervals were estimated using logistic regression to assess the association of demographic characteristics with having high knowledge (as defined above) of HPV disease, HPV-related cancers, and the HPV vaccine, respectively. Additionally, estimates of association were derived for each individual cancer comprising the HPV-related cancer knowledge score. Proportions on the benchmark items were calculated and tested using a one-sample proportion test. The null hypothesis being that the VIM proportion equals the national benchmark (HINTS) estimate. HINTS data were weighted to provide estimates of the U.S. population as well as correct for nonresponse bias. All analyses were performed using SAS 9.4. Statistical comparisons were two-sided and were considered significant at the $P < 0.05$ level.

Results

During the study period, a total of 356 patients were eligible to participate. Of these, 301 patients accepted a survey and 55 declined (84% participation rate). Of the 301 surveys returned, five were excluded from analysis due to excessive missing data; a total of 296 surveys were

Procedures

 Volunteers in Medicine staff recruited a convenience sample of patients attending clinical appointments during the study period (September 10, 2014–October 24, 2014).
included in the analyses. While the study participants were all adults, 230 (79%) indicated that they had children. Of 183 participants who indicated their children’s age, 111 (61%) had at least one child who would be age-eligible for HPV vaccination (ages: 9–26).

The study sample closely reflected the overall demographics of the VIM patient population (described above). Specifically, 78% of the sample was female, 51% were black or African American and 10% were Hispanic, with a median age of 49 years. Additional demographic characteristics are shown in Table 1. The sample differed somewhat from the population of Duval County, FL, which is 51.5% female, 29.4% black or African American, and 8.1% Hispanic, with a median age of 35.9 years (http://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=CF).

Overall, 50.3% (n = 149) of the sample reported they had heard of human papillomavirus or HPV, and 32.1%

### Table 1. Demographics for total sample and by HPV disease awareness and HPV vaccine awareness.

| Characteristic | Total sample (n = 296) | Heard of HPV (Yes) (n = 149) | Heard of HPV Vaccine (Yes) (n = 95) |
|---------------|------------------------|------------------------------|-----------------------------------|
| Age (years)   |                        |                              |                                   |
| Mean (SD)     | 47.1 (10.1)            | 45.2 (10.5)                  | 45.4 (10.0)                       |
| Median (Q1, Q3)| 49 (41, 54)            | 46 (38, 53)                  | 47.5 (39, 52)                     |
| Sex           |                        |                              |                                   |
| Female        | 225 (77.9)             | 129 (87.2)                   | 85 (90.4)                         |
| Male          | 64 (22.1)              | 19 (12.8)                    | 9 (9.6)                           |
| Race          |                        |                              |                                   |
| Black         | 150 (50.7)             | 73 (49.0)                    | 40 (42.1)                         |
| White         | 114 (38.5)             | 65 (43.6)                    | 51 (53.7)                         |
| Other         | 32 (10.8)              | 11 (7.4)                     | 4 (4.2)                           |
| Ethnicity     |                        |                              |                                   |
| Hispanic      | 25 (9.8)               | 11 (8.0)                     | 10 (11.2)                         |
| Not Hispanic  | 231 (90.2)             | 127 (92.0)                   | 79 (88.8)                         |
| Education     |                        |                              |                                   |
| ≤High school  | 140 (49.0)             | 51 (34.9)                    | 27 (29.3)                         |
| Some college/technical school | 102 (35.7)          | 68 (46.6)                    | 45 (48.9)                         |
| >College      | 44 (15.4)              | 27 (18.5)                    | 20 (21.7)                         |
| Marital status|                        |                              |                                   |
| Single        | 71 (24.5)              | 36 (24.3)                    | 23 (24.5)                         |
| Married/partnered | 110 (37.9)         | 57 (38.5)                    | 37 (39.4)                         |
| Other2        | 109 (37.6)             | 55 (37.2)                    | 34 (36.2)                         |
| Have children |                        |                              |                                   |
| Yes           | 230 (78.8)             | 110 (73.8)                   | 73 (76.8)                         |
| No            | 62 (21.2)              | 39 (26.2)                    | 22 (23.2)                         |
| Number of children |        |                              |                                   |
| Mean (SD)     | 2.12 (1.78)            | 1.77 (1.54)                  | 1.89 (1.51)                       |
| Median (Q1, Q3)| 2 (1, 3)               | 2 (0, 3)                     | 2 (1, 3)                          |

HPV, Human papillomavirus; SD, standard deviation.

1 Frequencies and percent of nonmissing responses are reported.
2 Separated, divorced, widowed.

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

### Discussion

Awareness and knowledge of HPV disease, HPV vaccines, and HPV-related cancers was low among working, uninsured adult patients receiving care in a volunteer-based community health clinic. Only half of survey respondents had heard of HPV; this estimate is similar to that reported by Fowler and colleagues among a community-based sample of Latinas in the United States [29]. Further, less than
### Table 2. Logistic regression assessing demographic predictors of high knowledge1.

| Characteristic                  | HPV knowledge OR (95% CI) | HPV vaccine knowledge OR (95% CI) | Cancer knowledge OR (95% CI) |
|--------------------------------|---------------------------|----------------------------------|-----------------------------|
| **Unadjusted models**          |                           |                                  |                             |
| Age (continuous)               | 0.96 (0.93, 0.99)         | 0.98 (0.96, 1.01)                | 0.98 (0.95, 1.02)           |
| Sex (Female)                   | 2.22 (0.90, 5.48)         | 2.83 (1.16, 6.94)                | 1.21 (0.47, 3.09)           |
| Race (white)                   | 2.15 (1.15, 4.01)         | 1.88 (1.05, 3.36)                | 2.10 (0.99, 4.45)           |
| Ethnicity (Hispanic)           | 1.16 (0.41, 3.27)         | 0.98 (0.35, 2.74)                | 1.08 (0.30, 3.84)           |
| Education (> High School)      | 2.97 (1.49, 5.90)         | 4.60 (2.31, 9.16)                | 2.93 (1.26, 6.82)           |
| **Adjusted models**            |                           |                                  |                             |
| Age (continuous)               | 0.95 (0.92, 0.99)         | 0.98 (0.95, 1.02)                | 0.98 (0.94, 1.01)           |
| Sex (Female)                   | 1.99 (0.77, 5.17)         | 2.93 (1.06, 8.08)                | 1.24 (0.44, 3.50)           |
| Race (White)                   | 2.58 (1.28, 5.21)         | 2.39 (1.21, 4.68)                | 1.63 (0.72, 3.68)           |
| Ethnicity (Hispanic)           | 1.03 (0.35, 3.05)         | 0.85 (0.28, 2.54)                | 1.02 (0.28, 3.75)           |
| Education (> High School)      | 2.34 (1.14, 4.84)         | 5.04 (2.30, 11.06)               | 2.25 (0.94, 5.38)           |

CI, confidence interval; OR, odds ratio; HPV, Human Papillomavirus; Significant ORs in boldface.

1High knowledge defined as a knowledge score ≥75th percentile (of knowledge scores ≥1). Referent groups: Sex (Male); Race (nonwhite); Ethnicity (non-Hispanic); and Education (≤ High School).

### Table 3. HPV-related cancer knowledge among VIM sample and HINTS Cycle 4 respondents.

| HPV can cause       | VIM sample N (%) correct | HINTS Cycle 41 N (%) correct | P-value | N (%) correct |
|---------------------|--------------------------|------------------------------|---------|---------------|
| Cervical cancer2    | 130 (43.9)               | 1649 (49.0)                  | 0.0803  |               |
| Penile cancer2      | 34 (11.5)                | 574 (18.1)                   | 0.0031  |               |
| Anal cancer2        | 27 (9.1)                 | 526 (16.0)                   | 0.0012  |               |
| Throat cancer2      | 33 (11.1)                | 638 (18.5)                   | 0.0011  |               |
| Vaginal/vulvar cancer2 | 91 (30.7)          | –                            | –       |               |
| Lung cancer2        | 77 (26.0)                | –                            | –       |               |
| Breast cancer3      | 70 (23.6)                | –                            | –       |               |
| Prostate cancer3    | 33 (11.1)                | –                            | –       |               |
| Skin cancer2        | 57 (19.3)                | –                            | –       |               |

VIM, volunteers in medicine clinic; HPV, Human Papillomavirus; –, data not available.

1Health Information National Trends Survey (HINTS) data are unweighted responses and estimated weighted percent.

2Correct answer = yes.

3Correct answer = no.

one-third of VIM clinic patients surveyed had heard of a vaccine to prevent HPV and a majority of our respondents did not know the causative relationship between HPV and many cancers. The low rates of knowledge of HPV disease and the availability of prophylactic vaccines observed in this sample of medically underserved adults in the United States are consistent with rates reported among a population-based survey of young adult women in Morocco [30] and a systematic review of 14 studies conducted in African countries [31]. Knowledge of the causal link between cancer and HPV was highest for cervical cancer. However, fewer than half of respondents were aware of this association. Knowledge of the link between HPV and throat cancer was strikingly low, at 11% of the sample. This finding is consistent with a reported range of between 1 and 44% for general (nonmedical or dental professional) population samples in a recent systematic review [32]. Oropharyngeal cancer affects both men and women and is increasing in incidence in several developed countries, including the United States [33–35]. The lack of knowledge of HPV as a risk factor for oropharyngeal cancer, the increasing prevalence of oropharyngeal cancer, an increased risk of this cancer for males as compared to females, and unavailability of screening [35] should draw attention to the need for vaccine efficacy data in this cancer and universal HPV vaccine recommendations in countries where they currently do not exist.

These findings underscore a crucial need for strategies to educate medically underserved adults about HPV and to offer information about the HPV vaccine and, if resources permit, offer the vaccine in all clinic settings. Volunteer clinics should be a priority for HPV vaccine initiatives because they reach particular populations (e.g., uninsured, female, racial minority) that have disproportionately lower HPV vaccine coverage and higher rates of several HPV-associated cancers [22]. While this clinic assists working individuals without insurance who meet certain income requirements, we estimate that 40–50% would have at least one child who is eligible for the HPV vaccine. Increasing the knowledge of the clinic patients about the HPV vaccine and community resources available for children to be vaccinated may mediate an increase in vaccinations of their age-eligible children. Maximizing access to HPV information, factual knowledge, and vaccination, including catch-up vaccination for adults up to age 26, is consistent with the recommendations of the American College of Obstetricians and Gynecologists, the American College of Physicians, the Advisory Committee on...
Immunization Practices and addresses all three of the goals within the President’s Cancer Panel Report [25]. Indeed, this report recommends increasing the range of settings in which HPV vaccines may be administered.

Decades of work in cancer prevention, early detection, and treatment have resulted in declining death rates for many cancers in the United States; however, the gains afforded by such efforts have not been equally enjoyed by those belonging to economically and socially disadvantaged groups [36]. Cancer remains a highly-feared disease and a complex condition that is associated with significant morbidity and mortality. Communication strategies that frame HPV vaccines as vaccines to prevent cancer may increase acceptance and coverage. Toward this end, the nation’s National Cancer Institute-designated cancer centers recently endorsed a statement promoting HPV vaccination as a cancer prevention tool, in the first unanimous endorsement of its kind (http://www.asco.org/sites/www.asco.org/files/nci_hpv_consensus_statement_012716.pdf).

Prior research suggests that educational efforts emphasizing the diseases that vaccines prevent may be more effective in reducing vaccine hesitancy than educational interventions aimed at dispelling misconceptions about the vaccine [37]. Thus, adopting a cancer-prevention dialog may effectively divert the provider-adolescent-parent conversation away from sexual activity. Instead, the conversation could be directed toward a discussion of primary and secondary prevention of future cancers by getting the HPV vaccine and not initiating (or stopping) cancer-risk behaviors that often start in young adulthood (e.g., tobacco use, tanning).

This study reveals gaps in knowledge and awareness of HPV vaccines in a United States sample of uninsured, socioeconomically disadvantaged adults when benchmarked against national estimates obtained during the same year. These gaps in knowledge potentially exist in other, similarly disadvantaged groups in the United States more than 10 years after the vaccine was licensed for use among females, and several years after being recommended for males. Our findings suggest that some of the most vulnerable individuals remain unaware of a ubiquitous virus that can cause cancer and the existence of a safe and effective vaccine to protect against it. These findings, while not without the limitations associated with a convenience sample of relatively small size obtained from a single clinic setting, are important and point to settings and populations in which HPV vaccine initiatives remain critical.

Acknowledgments

We gratefully acknowledge the contributions of Volunteers in Medicine (VIM) staff and the participation of VIM patients in this study. We also acknowledge the scientific contributions of Mignonne C. Guy, PhD in the planning and execution of this community-based project.

Conflict of Interest

None declared.

References

1. Walboomers, J. M., M. V. Jacobs, M. M. Manos, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12–19.
2. Muñoz, N., F. X. Bosch, S. de Sanjosé, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518–527.
3. IARC Working Group on the Evaluation of Carcinogenic. 2012. Risks to Humans. Biological agents: a review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100B:1–441.
4. Forman, D., C. de Martel, C. J. Lacey, et al. 2012. Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12–F23.
5. zur Hausen, H.. 2009. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:260–265.
6. Lowy, D. R., and J. T. Schiller. 2012. Reducing HPV-associated cancer globally. Cancer Prev. Res. (Phila.) 5:18–23.
7. Bouvard, V., R. Baan, K. Straif, et al. 2009. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 10:321–322.
8. Viens, L. J., S. J. Henley, M. Watson, et al. 2016. Human papillomavirus-associated cancers - United States, 2008-2012. MMWR Morb. Mortal. Wkly Rep. 65:661–666.
9. Dobson, S. R., S. McNeil, M. Dionne, et al. 2013. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309:1793–1802.
10. Kreimer, A. R., M. E. Sherman, V. V. Sahasrabuddhe, and M. Safaeian. 2015. The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. J. Natl Cancer Inst. 107: dju436.
11. Lamontagne, D. S., V. D. Thiem, V. M. Huong, Y. Tang, and K. M. Neuzil. 2013. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J. Infect. Dis. 208:1325–1334.
12. Sankaranarayanan, R., P. R. Prabhu, M. Pawlita, et al. 2016. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in
13. World Health Organization. 2014. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol. Rec. 89:465–491.

14. Audisio, R. A., G. Icardi, A. M. Isidori, et al. 2016. Public health value of universal HPV vaccination. Crit. Rev. Oncol. Hematol. 97:157–167.

15. Crosignani, P., A. de Stefani, G. M. Fara, et al. 2013. Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health 13:642.

16. Stokley, S., J. Jeyarajah, D. Yankey, et al. 2014. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR Morb. Mortal. Wkly Rep. 63:620–624.

17. Markowitz, L. E., E. F. Dunne, M. Saraiya, et al. 2014. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 63(RR05):1–30.

18. Petrosky, E., J. A. Jr Bocchini, S. Hariri, et al. 2015. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb. Mortal. Wkly Rep. 64:300–304.

19. Committee Opinion No. 2015. 641: human papillomavirus vaccination. Obstet. Gynecol. 126:e38–e43.

20. Reagan-Steiner, S., D. Yankey, J. Jeyarajah, et al. 2015. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR Morb. Mortal. Wkly Rep. 64:784–792.

21. Jeudin, P., E. Liveright, M. G. Del Carmen, and R. B. Perkins. 2014. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates. Clin. Ther. 36:24–37.

22. Jemal, A., E. P. Simard, C. Dorell, et al. 2013. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J. Natl Cancer Inst. 105:175–201.

23. Holman, D. M., V. Benard, K. B. Roland, M. Watson, N. Liddon, and S. Stokley. 2014. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 168:76–82.

24. Jacobson, R. M., and A. A. Agunwamba, J. L. St Sauver, L. J. Finney Rutten. 2016. The most effective and promising population health strategies to advance human papillomavirus vaccination. Expert. Rev. Vaccines 15:257–269.

25. Accelerating HPV vaccine uptake: urgency for action to prevent cancer. 2014. A Report to the President of the United States from the President’s Cancer Panel. Bethesda, MD: National Cancer Institute. Available from URL: http://deainfo.nci.nih.gov/advisory/pcp/annualReports/HPV/index.htm [accessed May, 9, 2016].

26. Waller, J., R. Ostini, L. A. Marlow, K. McCaffery, and G. Zimet. 2013. Validation of a measure of knowledge about human papillomavirus (HPV) using item response theory and classical test theory. Prev. Med. 56:35–40.

27. Nelson, D. E., G. L. Kreps, and B. W. Hesse, et al. 2004. The health information National Trends Survey (HINTS): development, design, and dissemination. J. Health Commun. 9:443–460; discussion 81-84.

28. Health Information National Trends Survey. 2016. Cycle 4, English version. Annotated form and Methodology Report. Available from URL: http://hints.cancer.gov [accessed 9 May 2016].